Validated long-acting delivery platform for GLP-1 small molecules and peptides
[by Ji, Yong Jun] Inventage Lab, a company specializing in drug delivery platform technologies, announced on January 28 that it has secured a patent in Korea for its technology enabling the formulation of ‘orforglipron,’ a small-molecule compound garnering attention as a next-generation therapy for obesity and diabetes, into a long-acting injectable dosage form.
Orforglipron, for which a domestic 카지노 바카라 has been granted, is an orally (ingestible) administered small-molecule compound currently under development by the multinational pharmaceutical company Eli Lilly and belongs to the glucagon-like peptide 1 (GLP-1) class of drugs. Orforglipron has demonstrated remarkable weight-reduction efficacy in patients with obesity.
The company noted that this domestic 카지노 바카라 registration represents the first 카지노 바카라 to date to secure rights for formulating orforglipron as a long-acting injectable. Inventage Lab has already completed an international application under the 카지노 바카라 Cooperation Treaty (PCT) and plans to expedite the acquisition of global intellectual property rights by pursuing national phase entries in major markets, including the United States, Europe, and Japan.
Inventage Lab has demonstrated the robustness of its formulation technology by securing key patents covering the application of GLP-1-class small-molecule compounds and peptide drugs to its ‘IVL-DrugFluidic’ platform. This technology enables stable encapsulation within biodegradable polymers and the production of uniform microparticles. In addition, through a patent based on ‘semaglutide,’ a compound under co-development with Yuhan Corporation, the company successfully obtained rights to a pharmacodynamic control technology that modulates the initial release following intravenous administration while maintaining stable systemic blood concentrations over an extended period.
Inventage Lab has further demonstrated the versatility of this platform by successfully securing a 카지노 바카라 for converting orforglipron, an orally administered once-daily medication, into a single-injection formulation through the application of its IVL-DrugFluidic technology, enabling sustained efficacy for one to three months. According to the company, this technological breakthrough substantially improves patient adherence by eliminating the burden associated with daily dosing.
The company emphasized that the core innovation of this patent lies in its ‘precise control of the initial release profile.’ Inventage Lab explained that, by minimizing the initial release rate in accordance with the stringent parameters defined in the patent claims, the formulation reduces gastrointestinal adverse events (nausea, vomiting, and diarrhea) commonly associated with rapid increase in drug concentration following oral administration. Furthermore, it enhances bioavailability to maintain stable therapeutic effects over an extended period.
"Through our existing core patent portfolio, together with these first patents for orforglipron, we have demonstrated that our company holds one of the most advanced long-acting formulation technologies in the field of obesity therapeutics. Leveraging this technological foundation, we will continue to expand the application of long-acting injectable formulations to a broad range of peptide- and small-molecule compound-based obesity and metabolic disease treatments," said Kim Ju-hee, CEO of Inventage Lab.